A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
about
Farnesyl transferase inhibitor resistance probed by target mutagenesisNew targets for therapy in breast cancer: farnesyltransferase inhibitors.The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distributionActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsPotential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesAmide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsTargeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaFarnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasContext-dependent antagonism between Akt inhibitors and topoisomerase poisons.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.RhoB: Team Oncogene or Team Tumor Suppressor?C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes.
P2860
Q24684154-BF97D34C-841C-4C4C-A0BA-94BE5BDD9CC2Q24796277-3AE98C63-5C33-4D08-B33E-1EBF1DCE9813Q24805139-DE53C0D1-5CAC-43AF-9C8A-84844B9F2507Q27027458-E1390A91-A728-4603-A998-4986DFA6189DQ28391383-F2906700-D574-462F-B749-575BAD44A60AQ33246884-8E3A23BE-689B-4BF0-B1C5-1CEDDCF8AD6EQ33377668-3FFEE618-E840-4BA1-B526-15056C318F6FQ33779007-A26680A4-27EB-469D-A05C-DF3361BA6F10Q33914284-F8C32BDA-D9A2-477A-97D3-E09521B812A3Q35628954-7C808D9D-8A7C-4202-BAB9-E428653AA7D2Q36693797-DAC0D071-3D71-412F-B8F9-CB1DEC33FD42Q37708115-3CB6CD67-AEFA-4EC4-A5C7-F12103DA77FFQ40149906-C0E36C69-4958-4314-9473-5B4456468A59Q47100171-07B3AE7E-8346-4935-B9EB-A6622786926AQ49550467-35248CB7-D7C5-4A8A-87A1-AB6FC045DC52Q50045673-C5A9EACB-9B14-4DD3-B975-DDD09771D5A8
P2860
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
A Phase I trial of the farnesy ...... logical and clinical activity.
@en
type
label
A Phase I trial of the farnesy ...... logical and clinical activity.
@en
prefLabel
A Phase I trial of the farnesy ...... logical and clinical activity.
@en
P2093
P1433
P1476
A Phase I trial of the farnesy ...... ological and clinical activity
@en
P2093
C Erlichman
D L Cutler
L J Hanson
P A Svingen
P Atherton
P Kirschmeier
P304
P407
P577
2000-04-01T00:00:00Z